Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1615 details
Primary information
ThPP IDTh1133
Therapeutic Peptide/Protein NameAflibercept
SequenceSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLI view full sequnce in fasta
Functional ClassificationIb
Molecular Weight115000
Chemical FormulaC4318H6788N1164O1304S32
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeIntravitreal half life - 7.13 days
DescriptionAflibercept is a vascular endothelial growth factor (VEGF) inhibitor. It is a recombinant dimeric fusion glycoprotein that comprises (VEGF) binding portions from the extracellular domains of human VEGF receptors 1 and 2, this is fused to the Fc portion of human IgG1. It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa (protein part = 96.9 kDa). It has 5 putative N-glycosylation sites on each polypeptide chain and the attached carbohydrates exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the site associated with the Fc domain, which is unsialylated.
Indication/DiseaseThe opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
PharmacodynamicsCompared to other anti-VEGF drugs like bevacizumab and ranibizumab, aflibercept has a higher binding affinity to VEGF-A (Kd = 0.5 pM).
Mechanism of ActionAblibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.
ToxicityFor all intravitreal VEGF inhibitors, there is increased risk of stroke and myocardial infarction. An increase in intraocular pressure may also occur. When used intravenously, most common adverse reactions were leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache.
MetabolismBecause aflibercept is a protein, it is expected to be broken down via proteolysis into smaller peptides and amino acids. The cytochrome P450 enzyme system is not involved in the metabolism of aflibercept.
AbsorptionIn patients with wet AMD and CRVO, the mean peak plasma concentration (Cmax) was 0.02 mcg/mL and 0.05 mcg/mL respectively. These concentrations were reached in 1 to 3 days. Aflibercept did not accumulate when administered as repeated doses intravitreally every 4 weeks.
Volume of DistributionAfter Intravenous infusion of aflibercept, the volume of distribution is 6 L.
ClearanceWhen cancer patients were given 2-9 mg/kg every 2 or 3 week; 1 hour IV infusion of aflibercept the typical estimated clearances were as follows:CL of free aflibercept (CLf) = 0.88 L/day;CL of bound aflibercept (CLf) = 0.19 L/day;Patients clear free aflibercept faster if they had low albumin or high alkaline phosphatase levels.
CategoriesAntineoplastic Agents and Ophthalmics
Patents NumberUS7306799
Date of Issue26/03/09
Date of Expiry24/05/24
Drug InteractionN.A.
TargetVascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B
Information of corresponding available drug in the market
Brand NameEylea
CompanyRegeneron Pharmaceuticals
Brand DiscriptionEYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
Prescribed forNeovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Central Retinal Vein Occlusion (CRVO)
Chemical NameN.A.
FormulationEYLEA is supplied as a preservative-free, sterile, aqueous solution in a single-use, glass vial designed to deliver 0.05 mL (50 microliters) of EYLEA (40 mg/mL in 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 6.2).
Physcial AppearnceEYLEA is a sterile, clear, and colorless to pale yellow solution.
Route of AdministrationIntravitreal Injection
Recommended DosageThe recommended dose for EYLEA is 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).
Contraindicationocular or periocular infections, active intraocular inflammation, Hypersensitivity
Side EffectsEndophthalmitis and retinal detachments, Increased intraocular pressure, Thromboembolic events
Useful Linkhttp://www.rxlist.com/eylea-drug.htm http://www.eylea.com/international/?p=/eylea-home/index.php http://www.drugs.com/eylea.html
PubMed ID25646034, 25634529, 25632361, 25627086, 23673444, 23560774
3-D StructureTh1133 (View) or (Download)